CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings
CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
https://meetinglibrary.asco.org/record/162945/abstract
In a poster presentation at ASCO Sarah Bateni MD, a surgery resident at the University of California Davis Medical Center in Sacramento, reported survival outcomes from an analysis of National Cancer Database (NCDB) records of 11,406 men who had stage one, two or three breast cancer between the years 2004 and 2015. She discusses the findings with the Audio Journal of Oncology in the company of her colleague, Candice A. M. Sauder, MD, MEd, a Breast Surgical Oncologist at University of California Davis Medical Center.
Tags
Related Episodes
Young Women with HER2+ Early Breast Cancer Better with Mastectomy
Although breast conserving therapy has proved of equivalent efficacy to mastectomy in many patients with early breast cancer, mastectomy was associated with longer survival among those with HER2 posit
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries
CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.